TU‐C‐BRC‐02: Infrastructure to Integrate Imaging in Clinical Trials

Imaging biomarkers are increasingly used as primary or secondary endpoints in therapeutic trials. There are many academic units, professional organizations, industry groups and federal agencies addressing one or more components or issues associated with imaging biomarkers, and communication and coordination of efforts has been minimal. The RSNA has organized an Imaging Biomarkers Roundtable to establish ongoing communication among these organizations, and to develop a roadmap of activities and goals. Validation of imaging methods as biomarkers is complicated by the variability within and between patients, by the human observer component, by the variability across imaging devices from different manufacturers, and by the need to standardize methods across institutions and centers. To understand the errors and reduce them where possible, the Quantitative Imaging Biomarkers Alliance (QIBA) has been formed. These and other efforts are active and productive. Accomplishments and future plans will be discussed. Learning Objectives: 1. Understand efforts to integrate imaging biomarkers in clinical trials. 2. Understand efforts to improve the accuracy and precision of imaging biomarkers. © 2009, American Association of Physicists in Medicine. All rights reserved.

Duke Scholars

Author Daniel Carl Sullivan Radiology